Stay updated with breaking news from Brain Tumor Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investors often find stocks with momentum attractive because they have shown a recent trend of strong performance. The belief is that this trend may continue, offering the potential for profitable...
Investors are constantly on the lookout for catalysts that can influence price movements. One major driver that frequently affects stock prices is news, especially when it's positive. Such news has the potential to
Investors often follow stocks that gain momentum, and for good reason. These stocks tend to maintain their direction for a while, presenting opportunities for quick gains. In this feature, we'll take...
University Hospitals Is First in Cleveland To Offer GT Medical Technologies' New Targeted Therapy for Brain Tumors GammaTile® Therapy Is Shown To Slow Brain Tumor Progression, Designed To Improve Patient and Caregiver Quality of Life News provided by Share this article Share this article CLEVELAND, Feb. 17, 2021 /PRNewswire/ -- A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile ® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is de...
Press release content from Business Wire. The AP news staff was not involved in its creation. New Treatment for Central Nervous System Tumors Enters Phase I Clinical Trials January 12, 2021 GMT MINNEAPOLIS--(BUSINESS WIRE)--Jan 12, 2021-- OX2 Therapeutics, Inc., a privately held Minneapolis company, announces today that they treated their first patient in a phase one human trial of a new treatment developed to combat recurrent high-grade brain tumors. “This is a first-of-its kind immunotherapy that works to treat one of the most aggressive and deadly cancers today,” said Christopher Moert...